GET DAILY SIGNALSWhy Is Quanterix Corporation (QTRX) Stock Down -1.99% Today?
Key Takeaways
- QTRX shares slipped roughly 2% to $2.96, extending a pullback after last week's earnings-driven spike.
- The decline reflects profit-taking and consolidation following a sharp post-earnings rally, rather than a single new negative catalyst.
- Third-quarter revenue topped estimates, but a wider-than-expected per-share loss kept sentiment mixed on the company's path back to growth.
- Analyst commentary remains cautious, with firms holding "Hold"-equivalent ratings even as one target was raised to $4.
- Broader small-cap life sciences tools sentiment stayed subdued amid continued softness in academic and government research spending.
- Traders are watching whether the stock can hold support near recent lows and the next read on diagnostics and reimbursement momentum.
- For deeper detail, explore Price Targets, Earnings, and Forecast pages for QTRX.
- To see how algorithmic strategies are positioned across the market, visit the Trending AI Robots page.
Opening Summary
Quanterix Corporation (QTRX), a life sciences company that develops ultra-sensitive digital immunoassay platforms and spatial biology instruments for biomarker detection, traded lower on Wednesday. The stock fell about 2% to $2.96, down from a prior-session close of $3.02. The decline marks a continued unwind of the sharp rally that followed the company's third-quarter earnings release on November 9, when shares spiked before giving back a portion of those gains over subsequent sessions.
Post-Earnings Consolidation and Profit-Taking
The dominant driver behind today's move is consolidation after an earnings-driven surge. When Quanterix reported third-quarter results on November 9, revenue of roughly $35 million beat consensus expectations, and sequential revenue growth of 6.3% was framed by management as an early sign of a return to growth. The initial market reaction was strongly positive, sending shares sharply higher. However, the report also showed a wider-than-expected GAAP net loss per share, a reminder that profitability remains a longer-term objective.
With no fresh company-specific news on the session, the modest pullback on November 12 is most consistent with investors locking in gains from the earnings spike and reassessing valuation after the initial enthusiasm cooled. Shares had already declined over the prior two sessions, indicating that the post-earnings rally is being digested gradually.
Mixed Earnings and Cautious Analyst Stance
The earnings report itself presented a mixed picture. Top-line performance beat the Street, and management highlighted improving commercial execution, strong spatial consumables demand, and accelerating diagnostics bookings. The LucentAD Alzheimer's testing franchise doubled test volumes sequentially, and a favorable Florida Medicaid reimbursement decision expanded a key addressable market.
At the same time, the company continues to report net losses, and full-year guidance pointed to revenue of $142 million to $146 million, a range that leaves little room for upside surprises. Analyst reaction has been measured rather than bullish: TD Cowen raised its price target to $4 from $3.50 while maintaining a Hold rating, and Canaccord Genuity reiterated a Hold with a $3 target. This tempered tone, combined with the earnings miss on the bottom line, has kept a lid on sustained upside momentum.
Market Context and Trading Activity
Trading volume has been elevated since the earnings release, consistent with heightened investor attention around the print, though activity has tapered as the initial reaction faded. The pullback also aligns with lingering softness across the life sciences tools and diagnostics complex, where academic and government research budgets have remained constrained. Quanterix has acknowledged continued "market softness" in these segments, a headwind that weighs on instrument placements and consumables pull-through for peers in the sector.
Technically, the stock has pulled back from the post-earnings high near the $3.40 area and is now testing levels closer to its recent trading range. The move back toward $3 and below leaves shares closer to the lower end of the range established before the earnings catalyst, a level traders are watching closely for signs of stabilization.
What Comes Next for QTRX
Investors will be focused on whether Quanterix can convert its improving top-line trajectory into sustained momentum. Key watchpoints include continued sequential revenue growth, diagnostics partnership expansion, progress toward FDA-related milestones for its blood-based Alzheimer's biomarker tests, and further reimbursement wins in additional states. The company's cash position and ability to manage operating expenses will also remain in focus given its continued net losses.
Risks include persistent weakness in academic and government funding, competitive pressure in proteomics and spatial biology, and the possibility that the diagnostics ramp develops more slowly than anticipated. While analyst ratings lean cautious, any concrete evidence of accelerating growth or positive regulatory developments could shift sentiment. Conversely, a failure to hold current levels could see the stock retest recent lows.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Only the strongest performers are featured in this rotating selection. Traders seeking a data-driven complement to their own analysis may find it useful to explore the Trending AI Robots currently available.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QTRX in downward trend: price dove below 50-day moving average on November 11, 2026
QTRX moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where QTRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTRX as a result. In 75 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
QTRX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for QTRX just turned positive on November 09, 2026. Looking at past instances where QTRX's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 121 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. QTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of protein diagnostic platform
Industry MedicalNursingServices
Advertisement